Lei Pang

发表

Updated efficacy and safety of KEYNOTE-052: A single-arm phase 2 study investigating first-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC).

T. Powles, E. Plimack, D. Bajorin, 2018 .

Cellular and Humoral Responses to a Second Dose of Herpes Zoster Vaccine Administered 10 Years After the First Dose Among Older Adults.

K. Schmader, M. Levin, Z. Popmihajlov, 2016, The Journal of infectious diseases.

The Effect of Age on the Immunogenicity of the Live Attenuated Zoster Vaccine Is Predicted by Baseline Regulatory T Cells and Varicella-Zoster Virus-Specific T Cell Immunity

K. Schmader, M. Levin, Z. Popmihajlov, 2019, Journal of Virology.

Immunogenicity of Inactivated Varicella Zoster Vaccine in Autologous Hematopoietic Stem Cell Transplant Recipients and Patients With Solid or Hematologic Cancer

M. Boeckh, L. Camacho, V. Morrison, 2020, Open forum infectious diseases.

First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study.

T. Powles, E. Plimack, D. Bajorin, 2017, The Lancet. Oncology.

Pembrolizumab produces clinically meaningful responses as first-line therapy in cisplatin-ineligible advanced urothelial cancer: Results from subgroup analyses of KEYNOTE-052

T. Powles, E. Plimack, D. Bajorin, 2017 .

Inactivated varicella zoster vaccine in autologous haemopoietic stem-cell transplant recipients: an international, multicentre, randomised, double-blind, placebo-controlled trial

G. Papanicolaou, J. Mehta, J. Panse, 2018, The Lancet.

Safety and Immunogenicity of Inactivated Varicella-Zoster Virus Vaccine in Adults With Autoimmune Disease: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Clinical Trial

K. Papp, M. Eberhardson, S. Hall, 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Attenuating effects of omega-3 fatty acids (Omegaven) on irradiation-induced intestinal injury in mice.

M. Wei, Jiankun Yu, mingli Sun, 2014, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

Pembrolizumab (pembro) as first-line therapy for advanced/unresectable or metastatic urothelial cancer: Preliminary results from the phase 2 KEYNOTE-052 study

T. Powles, E. Plimack, D. Bajorin, 2016 .

Biomarker findings and mature clinical results from KEYNOTE-052: First-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC).

J. Lunceford, T. Powles, E. Plimack, 2017 .

Pembrolizumab as first-line therapy in cisplatin-ineligible advanced urothelial cancer: Results from the total KEYNOTE-052 study population.

T. Powles, E. Plimack, D. Bajorin, 2017 .

KEYNOTE-052: Phase 2 study of pembrolizumab (MK-3475) as first-line therapy for patients (pts) with unresectable or metastatic urothelial cancer ineligible for cisplatin-based therapy.

T. Choueiri, E. Plimack, G. Sonpavde, 2015 .

The safety and effectiveness of laparoscopic anterior sacral ligament suspension combined with dome suspension in the treatment of bladder prolapse after hysterectomy: a retrospective cohort study

Lei Pang, Weibing Shuang, Zijun Ding, 2023, Translational andrology and urology.

Persistence of Varicella-Zoster Virus Cell-Mediated Immunity After the Administration of a Second Dose of Live Herpes Zoster Vaccine

K. Schmader, M. Levin, Z. Popmihajlov, 2018, The Journal of infectious diseases.

A post hoc analysis utilizing the FDA toxicity grading scale to assess injection site adverse events following immunization with the live attenuated Zoster Vaccine (ZVL)

Z. Popmihajlov, A. Joshi, Lei Pang, 2018, Human vaccines & immunotherapeutics.

Pembrolizumab (pembro) plus epacadostat or placebo for locally advanced or metastatic urothelial carcinoma (UC) after failure of first-line platinum-containing chemotherapy: KEYNOTE-698/ECHO-303.

David C. Smith, T. Powles, H. Nishiyama, 2018 .

Boosting Immunity in Recipients of Live-Attenuated Zoster Vaccine

Judith M. Fonville, K. Schmader, G. Rimmelzwaan, 2015, The Journal of infectious diseases.

Phase 3, randomized, double-blind trial of pembrolizumab plus epacadostat or placebo for cisplatin-ineligible urothelial carcinoma (UC): KEYNOTE-672/ECHO-307.

E. Plimack, A. Balar, M. Santis, 2018 .